ATARA Biotherapeutics (ATRA) Misses Q4 EPS by 21c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. SPY
5. META
6. MSFT
7. GOOGL
8. GMAB
9. USO
10. AMD

Go back to ATARA Biotherapeutics (ATRA) Misses Q4 EPS by 21c

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

March 1, 2021 4:05 PM EST

On track to complete the rolling tab-cel® BLA submission in Q3 2021 for patients with EBV+ PTLD through active and productive discussions with FDA

On track with ATA188 Phase 2 RCT (randomized controlled trial) enrollment in patients with progressive forms of MS, enabling an interim analysis in H1 2022

Continued progress on advancing CAR T portfolio, enabling clinical data presentation for mesothelin-targeted ATA2271 in Q4 2021 and IND submission for novel allogeneic CD19 CAR T ATA3219 in Q4 2021/Q1 2022

Conference Call and Webcast Today at 4:30... More